CORDIS
EU research results

CORDIS

English EN

QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy

Objective

The QuIC-ConCePT consortium has 2 objectives:
1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proliferation, apoptosis, and necrosis, to allow drug developers to demonstrate reliably modulation of these pathologic processes in tumours in patients in realistic trials. Our vision for January 2016 is that drug developers can incorporate these IBs for decision-making in Phase I trials of investigational therapies, confident that the IBs are technically valid, that a measured change in the IB faithfully reflects the desired change in the underlying tumour pathology, and that the IBs can be readily deployed in multiple cancer centres in a robust, consistent, ethical, and cost-effective way acceptable to patients.
2.(10% of resource, WP6) includes a portfolio of innovative approaches to devise, evaluate and introduce IBs of invasion and metastasis.
The IBs of tumour cell proliferation and necrosis will be developed respectively from FLT PET and ADC MRI respectively. Initial apoptosis plans focus on ICMT11 PET, possibly with other IBs introduced later. The project will be delivered using a portfolio of animal (WP2), human (WP3), image analysis (WP4) and regulatory (WP5) work. The project will be coordinated and the interdependent workpackages integrated in WP1. These WPs will deliver image acquisition and analysis protocols which are technically valid, standardised and suitable for multicentre use. We will evaluate reproducibility, effects of intervention, timing, dose-response, and imaging-histopathology correlation in animals and patients. The project is timely, and highly likely to deliver IBs which will markedly improve drug development, and benefit cancer patients in Europe and globally. The managing entity (EORTC) is already world-leading in the qualification of IBs, and the consortium includes in the academic and EFPIA partners some of the world's most productive and innovative physicians and scientists in cancer imaging.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL

Address

Avenue E. Mounier 83
1200 Brussels

Belgium

Activity type

Research Organisations

EU Contribution

€ 1 251 050

Principal Investigator

Yan Liu (Dr PhD)

Administrative Contact

Stephane Lejeune (Mr)

Participants (23)

Sort alphabetically

Sort by EU Contribution

Expand all

ASTRAZENECA AB

Sweden

CANCER RESEARCH UK LBG

United Kingdom

EU Contribution

€ 88 511

THE UNIVERSITY OF MANCHESTER

United Kingdom

EU Contribution

€ 545 000

WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

Germany

EU Contribution

€ 290 250

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

EU Contribution

€ 225 000

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 340 000

STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC

Netherlands

EU Contribution

€ 732 400

STICHTING VUMC

Netherlands

EU Contribution

€ 613 000

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 55 000

UNIVERSITAIR ZIEKENHUIS ANTWERPEN

Belgium

EU Contribution

€ 445 000

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

United Kingdom

EU Contribution

€ 560 800

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Netherlands

EU Contribution

€ 210 000

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 775 000

Keosys S.A.S.

France

EU Contribution

€ 495 000

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

Switzerland

EU Contribution

€ 125 000

AMGEN

Belgium

Eli Lilly and Company Limited

United Kingdom

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

Merck KGaA

Germany

PFIZER LIMITED

United Kingdom

F. HOFFMANN-LA ROCHE AG

Switzerland

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 248 989

Project information

Grant agreement ID: 115151

Status

Closed project

  • Start date

    1 September 2011

  • End date

    31 December 2017

Funded under:

FP7-JTI

  • Overall budget:

    € 15 527 915

  • EU contribution

    € 7 000 000

Coordinated by:

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL

Belgium